Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!
- 21 October 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 17 (11) , 1009-1012
Abstract
Tobacco use represents the leading preventable risk factor for premature deaths worldwide. A meta-analysis of 74 epidemiological studies, including 3.2 million individuals with type 2 diabetes mellitus (T2DM) from 33 countries, reported a pooled prevalence of smoking of 20.8% among individuals with T2DM. Cigarette smoking further aggravates existing deleterious vascular effects of T2DM. Namely, chronic hyperglycemia and exposure to cigarette smoke cause additive injurious effect on the endothelium, leading to an acceleration of vascular complications seen in persons with T2DM and tobacco use disorders (TUD). In a recent study, Wang and colleagues found that semaglutide use was associated with a significantly lower risk for medical encounters for TUD, when compared to other antidiabetic drug classes; indeed, this effect was strongest compared with insulins and weakest compared with other glucagon-like peptide-1 receptor agonists. Semaglutide was associated with reduced smoking cessation medication prescriptions and counseling. Similar findings were observed irrespective of the presence of obesity. Therefore, semaglutide use might be useful in terms of smoking cessation among individuals with T2DM, thus offering an additional benefit for this constantly growing population. However, those interesting findings should be confirmed through dedicated, large-scale randomized controlled trials.Keywords
This publication has 14 references indexed in Scilit:
- Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidencePhysiology & Behavior, 2024
- GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetesCardiovascular Diabetology, 2024
- Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019The Lancet, 2021
- Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled TrialNicotine & Tobacco Research, 2021
- The global prevalence of tobacco use in type 2 diabetes mellitus patients: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2019
- Coronary heart disease incidence and mortality, and all-cause mortality among diabetic and non-diabetic people according to their smoking behavior in FinlandTobacco Induced Diseases, 2017
- Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidenceAtherosclerosis, 2017
- The effects of weight gain after smoking cessation on atherogenic α1-antitrypsin–low-density lipoproteinHeart and Vessels, 2014
- Cigarette Smoking Exacerbates and Its Cessation Ameliorates Renal Injury in Type 2 DiabetesThe American Journal of the Medical Sciences, 2004
- Smoking and Risk of Coronary Heart Disease Among Women With Type 2 Diabetes MellitusArchives of internal medicine (1960), 2002